Prostate cancer trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc is being studied. Conditions: Breast Cancer Invasive, Prostate Cancer • Eligibility: Pilot Phase Inclusion Criteria: 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South…. Goal: The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical…. Goal: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses is being studied. Conditions: Prostate Cancer (Adenocarcinoma) • Eligibility: Inclusion Criteria: For Patients: 1. Diagnosed with prostate cancer by a board-certified urologist. 2. Has either decided on a treatment plan or completed treatment within the past two…. Goal: This study aims to help patients with prostate cancer and their spouses cope better with the challenges of cancer by learning and supporting each other together. The investigators will test an 8-week "Dyadic Co-learning Intervention," which includes weekly learning topics, a mobile app, and professional support. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Taipei University of Nursing and Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effect of Education to be Provided to Patients to Undergo TURP With Mobile Application on Patient Outcomes is being studied. Conditions: Prostate Cancer (Post Prostatectomy) • Eligibility: Inclusion Criteria: * 18 years of age or older, * Written permission to participate in the study, * Conscious, oriented and cooperative, * Speaks and understands Turkish, *…. Goal: The aim of this study was to determine the effect of mobile application training on patient outcomes (preoperative anxiety, surgical fear, postoperative pain, hemodynamic parameters, satisfaction level and length of hospital stay) in patients undergoing transurethral prostate resection surgery. It was planned as a prospective, two-arm (1:1), randomized controlled clinical trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tarsus University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor is being studied. Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma • Eligibility: * INCLUSION CRITERIA: * Participants must have histologically confirmed, low or intermediate risk prostatic adenocarcinoma verified by biopsy (NIH Laboratory of Pathology confirmation is required). * Unifocal prostate…. Goal: Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue…. Goal: This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan is being studied. Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma • Eligibility: Inclusion Criteria: * Participants must have histologically or cytologically confirmed prostate cancer. * Age ≥18 years. * Participants must be planned for standard-of-care 177Lu-Vipivotide Tetraxetan therapy after the…. Goal: The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer). Phase/Status/Sponsor: Unknown phase; RECRUITING; Brigham and Women's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study With [225Ac]Ac-FL-020 in mCRPC Participants is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic CRPC. 2. Age ≥ 18 years. 3. Signed informed consent, and able and willing to comply with protocol requirements prior…. Goal: The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Full-Life Technologies GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy is being studied. Conditions: Cancer Of Prostate • Eligibility: * INCLUSION CRITERIA: * Participants must have histologically or cytologically confirmed localized intermediate or high risk prostate cancer: * Intermediate risk - Gleason 7 disease, PSA less than…. Goal: Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy is being studied. Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes +1 • Eligibility: Inclusion Criteria: * PHASE 1: Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * PHASE 2: ECOG performance status =\< 2 (Karnofsky \>= 60%)…. Goal: This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer is being studied. Conditions: Metastatic Prostate Cancer (mCRPC) • Eligibility: Key Inclusion Criteria: * Adult male patients with histologically or cytologically confirmed and documented adenocarcinoma of the prostate. * At least 1 bone or visceral metastatic lesion (according…. Goal: This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Continence, Sexual Function, Fitness and the Health of Men After Surgery for Prostate Cancer is being studied. Conditions: Prostate Cancer, Incontinence, Metabolic Disease • Eligibility: Inclusion Criteria: * have a diagnosis of prostate cancer (stage I to IV); * be scheduled for a prostatectomy surgery (any surgical approach); * have no restriction to…. Goal: The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer is being studied. Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the…. Goal: This phase I trial compares the effect of lutetium Lu 177 (177\^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177\^Lu-PSMA-617 alone in treating patients with prostate that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow and spread despite surgical or medical intervention to block androgen production (castration-resistant). 177\^Lu-PSMA-617, a type of radioconjugate, binds to a protein called PSMA, which is found on some prostate tumor cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collection of Blood From Patients With Cancer is being studied. Conditions: Prostate Cancer, Breast Cancer, Colon Cancer +2 • Eligibility: * INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2,…. Goal: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer is being studied. Conditions: Urinary Urge Incontinence, Stress Urinary Incontinence, Prostatic Hyperplasia • Eligibility: * INCLUSION CRITERIA: * Participants must be male. * Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment. *…. Goal: Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male * 18 years of age or older * Pathologically confirmed diagnosis of prostate adenocarcinoma * Non-metastatic prostate cancer * Planned radical prostatectomy at Massachusetts…. Goal: This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort is being studied. Conditions: Prostate Cancer, Magnetic Resonance Imaging, Population at Risk • Eligibility: Inclusion Criteria: 1. PSA between 1.0 and 2.5 ng/dL 2. High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate…. Goal: To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols. Phase/Status/Sponsor: Unknown phase; RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) is being studied. Conditions: Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant • Eligibility: Inclusion Criteria: * Histologically documented adenocarcinoma of the prostate confirmed by pathology report from prostate biopsy or a radical prostatectomy specimen. If prostatic tumor is of mixed histology,…. Goal: This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer is being studied. Conditions: Prostate Cancer Castration-resistant Prostate Cancer • Eligibility: Inclusion Criteria: To enter the trial, subjects had to meet all of the following eligibility criteria: 1. diagnosed metastatic castration-resistant prostate cancer (mCRPC); 2. Castration level of serum…. Goal: At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study. Based on the previous basic research, our company has developed CAR-NK cell injection, hoping to further evaluate its safety, tolerability and preliminary efficacy in the treatment of mCRPC patients in clinical studies, and provide new possibilities for the selection of clinical treatment strategies Phase/Status/Sponsor: Unknown phase; RECRUITING; Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation +3 • Eligibility: Inclusion Criteria: 1. Provide written informed consent; 2. Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; 3. Has Eastern Cooperative Oncology…. Goal: The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Acerand Therapeutics (Shanghai) Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer is being studied. Conditions: Prostate Cancer (Adenocarcinoma) • Eligibility: Inclusion Criteria: 1. Subjects must have biopsy-confirmed adenocarcinoma of the prostate. 2. Subjects must have a negative bone scan and CT scan or PSMA-PET for nodal or metastatic…. Goal: This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study. Phase/Status/Sponsor: Unknown phase; RECRUITING; The Methodist Hospital Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * An adult 18 to 100 years of age, * Able to read English or Spanish at least an eighth-grade level, * From a racial/ethnic background…. Goal: The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OPTIMUM-PCa: MRI- and PHI-Guided Prostate Cancer Diagnosis is being studied. Conditions: Prostate Cancer (Diagnosis), Prostate Cancer • Eligibility: Inclusion Criteria: * Male, aged 20 years or older * Serum PSA ≥3.0 ng/mL and ≤20.0 ng/mL and/or abnormal digital rectal -examination * Biopsy-naïve * Clinical stage ≤T2…. Goal: Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures. Although multiparametric MRI improves detection of clinically significant prostate cancer, optimal criteria for biopsy omission-particularly in men with equivocal MRI findings-remain uncertain. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; In Gab Jeong, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance is being studied. Conditions: Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques • Eligibility: Inclusion Criteria: * Male participants aged 45 to 75 years * Localized prostate cancer on active surveillance or newly diagnosed and eligible for active surveillance * Negative multiparametric…. Goal: Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease. Multiparametric MRI (mpMRI) is widely used to guide diagnosis and follow-up, but it can miss clinically significant prostate cancer and may be limited by access, cost, and variability in interpretation. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; McGill University Health Centre/Research Institute of the McGill University Health Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer • Eligibility: Key Inclusion Criteria: * Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed…. Goal: This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer is being studied. Conditions: Prostate Adenocarcinoma • Eligibility: Inclusion Criteria: 1. Age at least 21 years old 2. Histologically confirmed adenocarcinoma of the prostate 3. Study participant qualified and planning for radical prostatectomy 4. At least…. Goal: The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Alessa Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. is being studied. Conditions: Prostate Carcinoma • Eligibility: Inclusion Criteria: * Men aged 18-90 at study enrollment * History of prostate cancer * Men who have had focal therapy (laser, cryotherapy, high-intensity focused ultrasound \[HIFU\], Tulsa…. Goal: This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * histologically confirmed untreated primary prostate cancer patients; * 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week; * signed written consent. Exclusion Criteria: * known allergy against…. Goal: Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study is being studied. Conditions: Diabetes, Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate that is localized (no metastatic lesions or concerning lymph nodes 1cm or greater) based on prostate MRI and meets…. Goal: The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients is being studied. Conditions: Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy) +2 • Eligibility: Inclusion Criteria: 1. Participant must have a histologically diagnosed adenocarcinoma of the prostate 2. Participant has to be ≥ 18 years of age 3. Participant must have either…. Goal: Prostate cancer is the second most common cancer among men. Many patients experience a significantly reduced quality of life due to either the cancer itself or the side effects of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ludwig-Maximilians - University of Munich.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Life expectancy \>5 years * Age ≥18 years * World Health Organization (WHO) performance status 0-2 * Histological evidence of prostate cancer * Classified as…. Goal: HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Region Skane.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Participant must be 75 years of age or older, at the time of signing the informed consent. 2. Participants who are healthy as determined by…. Goal: It is currently unclear if immediate curative treatment (radiotherapy or surgery) of high-risk prostate cancer without metastasis in older men (\>=75 years) generates the same survival benefits as in younger patients or if the harms/ side-effects of immediate curative treatment outweigh the benefits. In this study the investigators randomize older patients with high-risk, non-metastatic high-risk prostate cancer to either immediate curative therapy or to conservative, more problem-oriented therapy to investigate if immediate curative treatment prolongs life, improves quality of life and is cost-effective. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sven Löffeler.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer is being studied. Conditions: Oligometastatic Prostate Cancer • Eligibility: Inclusion Criteria: 1. Patient must have histologically confirmed adenocarcinoma of the prostate. 2. Patient's primary prostate cancer tumor treated with surgery and/or radiation (+/- ADT). 3. Patients must…. Goal: This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progression-free survival (PFS), and hormone therapy-free survival and mitigate immunosuppressive changes to the tumor microenvironment (TME), compared to SBRT alone. Phase/Status/Sponsor: Unknown phase; RECRUITING; Catherine Spina.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Tulmimetostat (DZR123/CPI-0209) as a single-drug therapy for advanced solid tumors and lymphomas, and also in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) in a later cohort. It starts with Phase 1 to find the safe dose (MTD/RP2D) and then moves to Phase 2 to assess safety, tolerability, and early anti-tumor activity across several disease-specific groups (including ARID1A-mutant endometrial/urothelial cancers and M7) and a combination cohort (M8). Participants are adults with various advanced cancers, with certain molecular subtypes and measurable disease, all with good performance status and organ function. Key exclusions include active brain metastases, significant cardiovascular disease, recent major surgery, uncontrolled infections, and prior EZH2 inhibitors; for the M8 cohort, prior enzalutamide or other AR pathway inhibitors may also exclude eligibility.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study * Must have received at least one dose of AAA617 within an interventional,…. Goal: The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) • Eligibility: Inclusion Criteria: * Man with histologically confirmed prostate adenocarcinoma, initiating systemic therapy for metastatic disease, encompassing newly diagnosed (i.e. de novo) hormone sensitive prostate cancer (mHSPC) or first-line…. Goal: ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Phase/Status/Sponsor: Unknown phase; RECRUITING; Karolinska Institutet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stereotactic Ablative Radiation Therapy for Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study…. Goal: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR). Phase/Status/Sponsor: Unknown phase; RECRUITING; Medical University of South Carolina.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial) is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate (histological confirmation can be based on tissue taken at any time, but a re-biopsy should be considered if the…. Goal: The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to the National Comprehensive Cancer Network (NCCN) based on multimodal artificial intelligence (MMAI) classification. All patients will receive (i) a dose escalation to the prostate via HDR brachytherapy (boost), (ii) twelve months of ADT and (iii) extremely hypofractionated RT to the prostate (5 fractions). Phase/Status/Sponsor: Unknown phase; RECRUITING; German Oncology Center, Cyprus.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers is being studied. Conditions: Prostate Carcinoma, Erectile Function, Genito Urinary Cancer • Eligibility: Inclusion Criteria: * Patients aged ≤75 yrs; * PSA \<10 ng/mL * Prostate Cancer ISUP grade ≤2 and cT≤2 at prostate biopsy * undergoing nerve sparing RARP; *…. Goal: This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regina Elena Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy. * Maximum PSA value of 20 ng/ml. Exclusion Criteria: * Evidence of distant metastasis…. Goal: The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning. Phase/Status/Sponsor: Unknown phase; RECRUITING; Proton Collaborative Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate * pathologically confirmed T1-T3 disease * no sign of lymph node or metastatic disease…. Goal: This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival. Phase/Status/Sponsor: Unknown phase; RECRUITING; yair lotan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Metastatic Castration-Resistant Prostate Cancer (mCRPC) mCRPC refers to prostate cancer that progresses despite serum testosterone at castrate levels (\< 50 ng/dL or 1.7 nmol/L), meeting…. Goal: PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted radioligand. Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Fujian Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer is being studied. Conditions: Prostate Cancer, Prostate Cancer Metastatic • Eligibility: Inclusion Criteria: Stage 1: 1. Age 18-years-old or older 2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African…. Goal: The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Measuring Oncological Value of Exercise and Statin is being studied. Conditions: Prostate Cancer, Breast Cancer, Kidney Cancer +9 • Eligibility: Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is…. Goal: The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy is being studied. Conditions: Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate +2 • Eligibility: Inclusion Criteria: * Patients with increasing PSA after RP and clinical evidence of PET PSMA/Choline+ and MRI+ isolated prostatic bed relapse (IPBR) that is implantable via transperineal route…. Goal: The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy. The main question it aims to answer is: Does HDR Brachytherapy increase control rates and decreases complications compared with conventional External Irradiation? Phase/Status/Sponsor: Unknown phase; RECRUITING; Clinica Universidad de Navarra, Universidad de Navarra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Continuous Monitoring of Prostate Position During Radiotherapy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Patients undergoing definitive external beam radiotherapy; * Histological proven prostate adenocarcinoma * Prostate Specific Antigen (PSA),within 3 months prior to enrolment * Patient must be…. Goal: This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Royal North Shore Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Diagnosis of prostate adenocarcinoma as confirmed by the investigator * Metastatic disease documented by greater than or equal to (\>=) 1 bone lesions on 99mTc…. Goal: The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Aragon Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants is being studied. Conditions: Prostatic Neoplasms • Eligibility: Inclusion Criteria: * Participant is willing and able to give and sign a written informed consent for participation in the study * Male, aged 18 years or above…. Goal: This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Tethis S.p.A..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male, aged ≥18 years, with histologically confirmed adenocarcinoma of the prostate * Has already undergone prostate MRI and/or scheduled to undergo clinically indicated radical prostatectomy…. Goal: This single-center study will enroll 40 male participants to complete 2 diffusion magnetic resonance images within 30 days of each other. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of California, San Diego.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance) is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Age 18 years or above (no upper limit) * Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone…. Goal: The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)? Phase/Status/Sponsor: Unknown phase; RECRUITING; Imperial College London.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer is being studied. Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * Ability to understand and willingness to sign an informed consent form * Clinically localized grade group 1, 2, or 3 prostate cancer and unilateral magnetic…. Goal: This clinical trial evaluates the effectiveness of focal ablation with either focal cryotherapy or high intensity frequency ultrasound for the treatment of men with localized prostate cancer. Focal cryotherapy kills tumor cells by freezing them. Phase/Status/Sponsor: Unknown phase; RECRUITING; Marc Dall'Era, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: \- I. Males ≥ 18 years of age II. Histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell differentiation at the time of…. Goal: The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of British Columbia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer • Eligibility: Inclusion Criteria: * Male \>=18 years old. * Able to provide written informed consent and comply with the study procedures. * Participants with advanced and/or metastatic histologically or…. Goal: The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Syncromune, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) • Eligibility: Key Inclusion Criteria: mCRPC cohorts (men): 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2. PSA value at screening ≥4…. Goal: The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biopsy Under PSMA Radioligand Therapy is being studied. Conditions: Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer • Eligibility: Inclusion Criteria: * Patients with mCRPC eligble for PSMA RLT * In-lable use for PSMA RLT * PSMA PET/CT not older than 8 weeks prior to first cycle…. Goal: Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets the prostate-specific membrane antigen (PSMA). Phase/Status/Sponsor: Unknown phase; RECRUITING; Wuerzburg University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Micro-UltraSound In Cancer - Active Surveillance is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Adult men with Gleason Grade Group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy Exclusion Criteria: * Men who cannot…. Goal: This study will compare the two imaging modalities (MRI and micro-ultrasound) during Active Surveillance of prostate cancer (PCa). Progression to clinically significant PCa will be assessed by first taking micro-US targeted samples (while blinded to MRI results), followed by MRI targeted samples, finishing with 12 systematic biopsy cores. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented…. Goal: This is a multi-center, open-label, phase II, single-arm trial evaluating combination of darolutamide and high testosterone doses - extreme bipolar androgen therapy (ExBAT) - in patients with metastatic castration-resistant prostate cancer (mCRPC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Latin American Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer is being studied. Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features * Presence of metastatic disease that can be biopsied by…. Goal: This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is being studied. Conditions: mCRPC • Eligibility: Inclusion Criteria: 1. Male, aged 18 to 85 years. 2. Histologically confirmed prostate adenocarcinoma, without small cell carcinoma components. 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC) with disease progression…. Goal: This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Changzheng Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy is being studied. Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma +1 • Eligibility: Inclusion Criteria: * Histological diagnosis of adenocarcinoma of the prostate or documented history in medical records of having received treatment for prostate cancer diagnosis * Metastatic disease on…. Goal: This research trial studies gene expression in patients with prostate cancer that has spread to other places in the body receiving cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP-17) inhibition therapy. Studying samples of tissue, blood, and urine in the laboratory from patients receiving CYP-17 inhibition therapy may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of prostate adenocarcinoma. *…. Goal: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor inhibitor (ARI) is more effective against prostate cancer than pembrolizumab + ARI alone. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Weill Medical College of Cornell University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Age 18 and older * Confirmed diagnosis of prostate cancer * Men receiving standard-of-care ADT either for high-risk, locally advanced prostate cancer or as a…. Goal: Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), and via direct side effects of androgen deprivation therapy (ADT) resulting in a considerable physical and psychological burden. Recent studies demonstrated the efficacy of multimodal rehabilitation for functional recovery, improvements in QoL, reduction in cancer symptoms, and secondary and tertiary prevention. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests pencil beam scanning proton therapy using different doses and schedules to treat tumors that have come back in people who were previously treated with radiation to the same area. - It is for adults 18 years and older with a history of prior radiation and a good performance status (ECOG 0-2). - The researchers want to learn whether this targeted proton therapy can treat the cancer effectively while sparing healthy tissue, compared with past treatment approaches. - Exclusions include people with active non-cancer systemic diseases that would preclude treatment or follow-up, most prior invasive cancers unless disease-free for at least 3 years, and those with active connective tissue disorders such as lupus or scleroderma.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS is being studied. Conditions: Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging • Eligibility: Inclusion Criteria: * suspected prostate cancer warranting standard of care multi-core prostate biopsy Exclusion Criteria: * Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy…. Goal: A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Antelope Surgical Solutions, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer is being studied. Conditions: Prostate Adenocarcinoma • Eligibility: Inclusion Criteria: * Men aged ≥18 years at randomisation * The research subject must have capacity to sign a written informed consent document for the trial * WHO…. Goal: The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the prostate gland under ultrasound guidance. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Royal Surrey County Hospital NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed prostate cancer (mCRPC). 2. Must have evidence of metastatic disease on conventional imaging (eg. CT, MRI, technetium bone scan). May have…. Goal: TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation therapy (ADT), but recalcitrant disease recurs typically within 2-3 years, referred to as the Castration Resistant Prostate Cancer (CRPC). Androgen receptor (AR) targeted therapies, such as Enzalutamide (Enz) or Abiraterone (Abi), are FDA-approved therapeutics for CRPC patients. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; TechnoGenesys, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer Patients • Eligibility: Inclusion Criteria: 1. have the ability to understand and sign an approved informed consent form (ICF). 2. \>= 18 years old. 3. Eastern Cooperative Oncology Group (ECOG) performance…. Goal: The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC Phase/Status/Sponsor: Unknown phase; RECRUITING; Xiaorong Sun.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial is being studied. Conditions: High Risk Prostate Cancer • Eligibility: Inclusion Criteria: * Age \> 18 years * ECOG performance status ≤ 2 * Histologically proven prostate adenocarcinoma * High-risk group classification according to National Comprehensive Cancer Network…. Goal: Prostate Cancer (PCa) is the second most common malignancy and the 5th common cause of cancer-related mortality in men worldwide. The majority of patients with PCa is diagnosed with potentially curable disease and its management includes different approaches, such as surgery, Radiation Therapy (RT) and Androgen Deprivation Therapy (ADT), for exclusive use or in combination each other. Phase/Status/Sponsor: Unknown phase; RECRUITING; Istituto Clinico Humanitas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) is being studied. Conditions: Advanced Prostate Cancer • Eligibility: Inclusion Criteria: 1. Able and willing to provide a written informed consent. 2. Age 18-80 years old, gender unlimited. 3. The physical status score of the Eastern Tumor…. Goal: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC is being studied. Conditions: Prostatic Neoplasm • Eligibility: Key Inclusion criteria * Participants must be adults ≥ 18 years of age with signed informed consent prior to participation to study * Histologically or cytologically confirmed prostate…. Goal: The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 80 participants will be randomized. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer is being studied. Conditions: Prostatic Neoplasms • Eligibility: Inclusion Criteria: * Confirmed adenocarcinoma of the prostate which has spread to other body parts * Part 1: Prior treatment with at least 1 prior novel androgen receptor…. Goal: The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) is being studied. Conditions: Metastatic Hormone Sensitive Prostate Cancer • Eligibility: Inclusion Criteria: Double Blind treatment Phase: * Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.…. Goal: The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Astellas Pharma China, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE) is being studied. Conditions: Epidemiology, Prostate Cancer • Eligibility: Inclusion Criteria: * Group 1: A first negative prostate biopsy within 6 months * Group 2: serum-PSA level between 2.5-10 ng/mL and no prior prostate biopsy Exclusion Criteria:…. Goal: The risk of prostate cancer is associated with lifestyle habits, such as diet and physical activity. Indeed, results of numerous studies suggest links between obesity, diabetes, inflammation and androgen and estrogen metabolism in the pathogenesis of prostate cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CHU de Quebec-Universite Laval.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer is being studied. Conditions: Metastatic Prostate Cancer • Eligibility: Inclusion Criteria: For whole study: * Age ≥ 18 at the time of screening. * Histologically confirmed diagnosis of metastatic prostate cancer. * Candidate for treatment with enzalutamide,…. Goal: This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer is being studied. Conditions: Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm • Eligibility: Inclusion Criteria: 1. Male, aged 18-80 years; 2. PSA \> 4 ng/ml; 3. Patients meeting criteria for prostate biopsy: * fPSA/PSA \< 0.16 or PSA D \> 0.15…. Goal: This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Changzheng Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparing Rezum and Urolift is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male ≥ 50 years Symptomatic BPH International prostate symptom score (IPSS) ≥13 Prostate volume 30-80ml Exclusion Criteria: * History or high suspicion of prostate cancer…. Goal: This is a randomized controlled trial using a non-inferiority design with the subjects randomized 1:1 to either water vapour thermal treatment (REZUM) arm or prostatic urethral lift (UroLift) arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chinese University of Hong Kong.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery is being studied. Conditions: Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy • Eligibility: Inclusion Criteria: * Patients with persistent post prostatectomy erectile dysfunction as defined below: 1. Severe ED (IIEF score 5-7) and more than 12 months from prostatectomy OR 2.…. Goal: A single arm prospective pilot trial evaluating the 1-year erectile recovery outcomes and the safety of patients undergoing a somatic to autonomic nerve grafting procedure for restoration of erectile function in patients who have lost erectile function following radical prostatectomy for prostate cancer. During this study a total of 100 patients who have persistent erectile dysfunction for more than 18 months post prostatectomy will undergo a post radical prostatectomy nerve restoration procedure (PRP-NR). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Sir Mortimer B. Davis - Jewish General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors is being studied. Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer +5 • Eligibility: Inclusion Criteria: * diagnosed with any of the following cancers \[Stage I-III\]: breast, prostate, urinary bladder, and endometrial in the past 6 months; * being treated for cancer…. Goal: The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on "complex" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and/or hyperlipidemia) requiring medication management. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James is being studied. Conditions: Prostate Cancer • Eligibility: ARM A: Inclusion Criteria: * Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio…. Goal: This is a retrospective/prospective Analysis of surgical outcomes of robotic prostatectomy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study is being studied. Conditions: Prostate Adenocarcinoma • Eligibility: Inclusion Criteria: * Histologically confirmed, clinical localized adenocarcinoma of the prostate * No evidence of disease beyond the prostate and/or seminal vesicles (i.e., no suspicious pelvic lymph nodes…. Goal: This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a linear accelerator machine. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer is being studied. Conditions: Prostate Carcinoma • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age \>= 21 years * Patients undergoing SOC \[18F\]-DCFPyL PET-CT * Patients should be…. Goal: This clinical trial examines RefleXion Medical Radiotherapy System (RMRS) imaging to the standard of care (SOC) \[18F\]-DCFPyL positron emission tomography-computed tomography (PET-CT) imaging in patients with prostate cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of a tracer, \[18F\]-DCFPyL, that binds to prostate specific membrane antigen (PSMA) on tumor cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer is being studied. Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer +2 • Eligibility: Inclusion Criteria: 1. Prostate adenocarcinoma without distant metastatic disease with either Gleason score ≥ 7, PSA ≥ 10 ng/ml, or T2b or greater disease 2. Age \> 18…. Goal: This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial is being studied. Conditions: Prostate Carcinoma • Eligibility: Inclusion Criteria: * Age \>= 18 years * Histological confirmation of prostate cancer * Planned definitive dose radiotherapy to the prostate * Note: Patients are eligible for enrollment…. Goal: This clinical trial evaluates the effects of an empty bladder versus (vs.) a full bladder prior to undergoing a computed tomography (CT) simulation for radiation therapy in patients with prostate cancer. Radiation therapy is a commonly used treatment for men diagnosed with prostate cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Evaluation of Early Acupuncture for Immediate Continence Enhancement After Prostatectomy is being studied. Conditions: Prostate Cancer, Urinary Incontinence • Eligibility: Inclusion Criteria: 1. Patients who have undergone radical prostatectomy with a confirmed pathological diagnosis of prostate cancer. 2. One week post-radical prostatectomy (RP). 3. Karnofsky Performance Score (KPS)…. Goal: This study is being done to see if early acupuncture treatment can help men control their urination better right after their urinary catheter is removed following prostate cancer surgery (radical prostatectomy). Leaking urine is a very common problem immediately after this surgery, and current treatments often start after the catheter is already out. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Bin Xu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of INKmune in Patients With mCRPC (CaRe Prostate) is being studied. Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC • Eligibility: Inclusion Criteria: 1. Male subjects over 18 years of age at time of screening. 2. Blood Prostate Specific Antigen (PSA) of \>1.0 ng/ml at time of screening. 3.…. Goal: This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Inmune Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer is being studied. Conditions: Localized Prostate Cancer • Eligibility: Inclusion Criteria: * Language spoken: Finnish, English or Swedish * Mental status: Patients must be able to understand the meaning of the study * Informed consent: The patient…. Goal: Magnetic resonance imaging (MRI) has improved detection of clinically significant prostate cancer (PCa). MRI-guided transurethral ultrasound ablation (MRI-TULSA) system incorporates precise diagnosis and simultaneous ablation of prostate tissue enabling lesion-targeted treatment of PCa. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Brachytherapy for Prostatic Carcinoma Patients is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b (AJCC 6th Edition), N0, M0. Lymph node evaluation by either CT or MRI. 2.…. Goal: The goal of this clinical research study is to learn if a prostate implant (brachytherapy) can help to control intermediate risk prostate cancer. The safety of this procedure will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer is being studied. Conditions: Prostate CA • Eligibility: Inclusion Criteria: * ① Age ≥18 years and ≤85 years; * Histologically confirmed prostate cancer without small cell features; * Metastatic prostate cancer was identified by imaging examination…. Goal: The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; baotai Liang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) is being studied. Conditions: Bladder Cancer, Prostate Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult subjects (age ≥ 22 years) as required by local law 2. Subject has been indicated for a radical prostatectomy, radical cystectomy, or nephrectomy (partial…. Goal: This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Medtronic - MITG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Voluntarily participate in this clinical study, understand the research procedures, and are able to provide written informed consent. 2. Aged 18 to 80 years (inclusive),…. Goal: This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Leveraging EA8191 to Assess AI-Augmented EHR Abstraction is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Patient must be male and \>= 18 years of age. * Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic…. Goal: The goal of this prospective study is to assess the performance of AI (artificial intelligence) augmentation (compared against historical controls) to identify oncology patients who meet inclusion criteria for a clinical trial. The study staff will leverage a natural language processing (NLP)-based AI algorithm that rank-orders patients most likely to meet inclusion criteria for a trial. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Pennsylvania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer is being studied. Conditions: Prostate Carcinoma • Eligibility: Inclusion Criteria: * Have a diagnosis of prostate cancer and be scheduled to receive radiotherapy with concurrent androgen deprivation therapy, and presence of fatigue with severity of 1/10,…. Goal: This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central nervous system stimulant that can improve cognitive ability, mainly in memory and cognitive function. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of DXC014 in Patients With Advanced Solid Tumors. is being studied. Conditions: Small Cell Lung Cancer, Melanoma, Prostate Cancer +1 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements. 2. Male or female. 3. For other solid tumor patients: Age ≥18 years…. Goal: This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hangzhou DAC Biotechnology Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Creative Arts Therapy on Body Image, Self-esteem, Anxiety and Depression in Post-Treatment Prostate Cancer Patients is being studied. Conditions: Prostate Cancer, Creative Arts Therapy • Eligibility: Inclusion Criteria: * Adult participants diagnosed with localised prostate cancer, regardless of the stage and age 18 years or older; * are not currently receiving active therapy, including…. Goal: The goal of this clinical study is to assess the feasibility of implementing a creative arts therapy intervention of drawing and painting in Hong Kong prostate cancer patients and preliminarily examine the effects of this intervention on prostate cancer patients' health outcomes via a two-armed randomized controlled trial. The two arms will be (i) the creative arts therapy intervention group and (ii) a active control group. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; The Hong Kong Polytechnic University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of adenocarcinoma of the prostate status post radical prostatectomy * Completed written informed consent * Able and willing to complete EPIC, PORPUS,…. Goal: This phase I study will assess the toxicity profile and efficacy of SBRT (Stereotactic body radiotherapy) in patients with localized prostate cancer who are considered candidates for post-prostatectomy radiation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Documented histological or cytological evidence of adenocarcinoma of the prostate * Documented metastatic disease on bone scan and/or CT scans * Currently receiving enzalutamide, darolutamide,…. Goal: This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation androgen receptor (AR) directed therapy (e.g., enzalutamide, darolutamide, apalutamide and/or abiraterone). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Wisconsin, Madison.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prostate Irreversible Electroporation Study is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Men aged between 40 - 85 years * Visible index lesion(s) on MRI * Found to have localized prostate cancer after MRI-USG fusion targeted biopsy…. Goal: Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Chinese University of Hong Kong.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer is being studied. Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) • Eligibility: Inclusion Criteria: * Men over the age of 18 years * Histologically or cytologically confirmed adenocarcinoma prostate cancer * Metastatic disease confirmed either by a positive bone scan,…. Goal: This is an observational study in which only data are collected from participants receiving their usual treatment. In this study, data will be collected and studied from men with metastatic hormone-sensitive prostate cancer (mHSPC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) +2 • Eligibility: Inclusion Criteria: * Phase 1 Dose Escalation cohorts, Phase 1 Backfill cohorts, and Phase 2 Tumor Type-Specific cohort(s): must meet one of the following criteria: * HER2- metastatic…. Goal: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nuvation Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests botensilimab, an Fc-engineered anti-CTLA-4 monoclonal antibody, alone and in combination with balstilimab (anti-PD-1) in advanced solid tumors to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, and to identify the maximum tolerated dose and the recommended Phase 2 dose. - It is for adults with refractory, advanced cancers and will enroll up to about 550 evaluable participants across multiple cancer types, including NSCLC, melanoma, hepatocellular cancer, and others. - The trial uses a 3+3 dose-escalation design to determine dosing and will also explore safety, PK/PD, and potential clinical activity at doses deemed potentially effective. - Key exclusions include active brain metastases unless treated with specific criteria, active autoimmune disease requiring systemic therapy, active infection, pregnancy or breastfeeding, and certain recent or concurrent cancer therapies (prior CTLA-4 therapy may be allowed in some indications with sponsor agreement).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of COVID-19 on GU Disease is being studied. Conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions • Eligibility: Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects…. Goal: The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Icahn School of Medicine at Mount Sinai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer. is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Patients with BRCA mutation-positive metastatic castration-resistant prostate cancer * No history of previous use of this drug Exclusion Criteria: * None. Goal: The purpose of this study is to learn about the safety of TALZENNA in patients with BRCA mutation-positive metastatic castration-resistant prostate cancer. BRCA mutation positive means any changes to the BRCA gene. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes is being studied. Conditions: Ovarian Cancer, Prostate Cancer, Pancreas Cancer • Eligibility: Inclusion Criteria: * MSK patient age 18 years or older. * Diagnosed with or presumed by physician to have prostate cancer, or pancreatic cancer and recommended to undergo,…. Goal: This study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone. This is different from the usual approach to genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their patients to a genetic counselor in order to have these tests done, and the genetic counselors return the test results to the patient in person or over the telephone. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Radium 223 mCRPC-PEACE III is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of prostate adenocarcinoma * Asymptomatic or mildly symptomatic (defined as short form question #3 in Brief Pain Inventory worst pain must be…. Goal: The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; European Organisation for Research and Treatment of Cancer - EORTC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Subject has previously participated in the BP-007 clinical study and completed their IMRT treatment. 2. Subject agrees to complete all required follow-up visits. 3. Subject…. Goal: Long-Term Prospective Post Marketing Clinical Follow Up for Evaluation of the BioProtect Balloon Implant™ System Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BioProtect.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma within 365 days prior to randomization. * History/physical examination with digital rectal examination of the prostate and baseline toxicity assessment within…. Goal: The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Proton Collaborative Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer is being studied. Conditions: Prostatic Neoplasms • Eligibility: Inclusion Criteria: * Signed the informed consent form. * Male, aged ≥ 18 years. * Life expectancy ≥ 3 months. * Histologically or cytologically confirmed prostate adenocarcinoma. *…. Goal: This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring is being studied. Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 +4 • Eligibility: Inclusion Criteria: * Histologically confirmed (within 180 days prior to registration) adenocarcinoma of the prostate at high risk for recurrence as determined by the following criteria, according to…. Goal: This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; NRG Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation is being studied. Conditions: Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma • Eligibility: Inclusion Criteria: * Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment * Patients who are scheduled to undergo surgical excision or biopsy of a…. Goal: This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparative Study of MRI and TU in Identifying Clinically Significant Prostate Cancer Among Ethnic Groups is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male patients who are 40 years of age or older * Individuals who exhibit increased PSA values (e.g., PSA \>4 ng/mL) or abnormal results on…. Goal: This study is designed to compare the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Transrectal Ultrasound (TRUS) in detecting clinically significant prostate cancer, using histopathology (biopsy results) as the gold standard. Prostate cancer is a leading cause of cancer-related morbidity among men globally, and its detection often varies across ethnic groups due to genetic, environmental, and healthcare access factors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Superior University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of Ipatasertib in Combination With Atezolizumab is being studied. Conditions: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic • Eligibility: Inclusion Criteria: 1. PART A1: Patients with histologically or cytologically confirmed malignant advanced solid tumours refractory to conventional treatment, or for which no conventional therapy exists or is…. Goal: This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Institute of Cancer Research, United Kingdom.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial is being studied. Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8 +3 • Eligibility: Inclusion Criteria: * Histologically confirmed, clinical localized adenocarcinoma of the prostate * No evidence of disease beyond the prostate and/or seminal vesicles (i.e., no suspicious pelvic lymph nodes…. Goal: This trial studies the changes in long-term physician-scored genitourinary toxicity achieved in prostate cancer patients eligible for stereotactic radiation therapy when both patients and physicians have access to convincing but non-validated germline signature that can characterize patients as having a low or high risk of developing toxicity after radiation therapy. The information learned from this study may guide patients' and physicians' decisions on radiotherapy fractionation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a single-center, prospective interventional trial that will test genome profiling using a program called FPG500 with next-generation sequencing in non-metastatic prostate cancer patients. - It includes people with low-risk, high-risk, or locally advanced prostate cancer, including those undergoing surgery or being managed with active surveillance. - The study aims to identify actionable mutations linked to tumor progression or hidden metastasis to help tailor treatment and possibly intensify therapy earlier. - Exclusions include having another cancer (past or present) and currently receiving androgen suppression or other medical treatments for prostate cancer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC is being studied. Conditions: Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) • Eligibility: Inclusion Criteria: 1. Age≧ 18 years old, male; 2. Physical condition ECOG score 0\~1 points; 3. Expected survival of at least 6 months; 4. Prostate adenocarcinoma confirmed by…. Goal: Acetate abiraterone tablets (II) is a modified new drug launched in China, prepared using nanocrystal technology and supplemented with SNAC as an absorption enhancer, working together to promote the gastrointestinal absorption of Abiraterone, improve its oral bioavailability, and reduce its pharmacokinetic variability within individuals, as well as the impact of food on its pharmacokinetics. According to preliminary research results, the exposure to 300mg acetate abiraterone tablets (II) under fasting conditions is not less than the exposure to the original Zeke® 1000mg, and the food effect of acetate abiraterone tablets (II) is small, allowing for medication without dietary restrictions. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ding-Wei Ye.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria include: * Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature * NCCN Intermediate Risk is defined…. Goal: The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria include: * Histologically confirmed adenocarcinoma of the prostate * Patients choosing active surveillance * Patients meeting definition of NCCN low risk, intermediate risk OR patients having…. Goal: The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Age \> or = 70 years and/or Charlson comorbidity index score \> or = 2 * Pathologically (histologically) proven diagnosis of prostatic adenocarcinoma * Two…. Goal: The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care. The study will also compare survival rates between patients receiving oral hormone therapy and those receiving standard of care. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms is being studied. Conditions: Prostate Cancer, Metastatic Prostate Cancer • Eligibility: Inclusion Criteria: 1. Diagnosed with prostate cancer within 6 months of screening visit 2. Metastatic disease (Any T, Any N, M1+) of any grade, stage or Prostate Specific…. Goal: Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Imperial College London.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether high-risk prostate cancer patients can be safely treated with a shorter 5-week hypofractionated radiotherapy course (68 Gy in 25 fractions) compared with the standard 7–8 week course (76 Gy in 38 fractions), using 3D-CRT or IMRT. - It is for men with high-risk, localized prostate cancer defined by features such as T3/T4, Gleason score over 8, or PSA over 20, with no nodal or distant metastases. - Participants will also receive 28 months of androgen deprivation therapy, and the trial will evaluate safety and efficacy outcomes. - The primary outcome is acute and late toxicity; secondary outcomes include biochemical failure, prostate cancer mortality, bone metastases–free survival, and biomarker and quality-of-life measures. - Key exclusions include prior chemotherapy for prostate cancer, prior pelvic radiotherapy, other active cancers, or life expectancy under 3 years; the trial is currently not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study is being studied. Conditions: Prostate Cancers • Eligibility: Inclusion Criteria: \- 1. Patients with histologically confirmed prostate cancer (PC) deemed suitable for endocrine therapy (excluding neoadjuvant endocrine therapy). 2\. At least 18 years old 3. Prescribed…. Goal: Prostate cancer (PC) is the most common malignancy in the male genitourinary system. In China, both the incidence and mortality rates of PC have shown a significant upward trend in recent years. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Qianfoshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. is being studied. Conditions: Benign Prostatic Hyperplasia • Eligibility: Inclusion Criteria: * Subject is 50 - 99 years of age * Subject has provided informed consent * Subject has diagnosis of prostate cancer requiring SBRT * Subject…. Goal: Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT). Phase/Status/Sponsor: Unknown phase; SUSPENDED; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs is being studied. Conditions: Prostate Cancer, Resistance, Disease, MicroRNAs • Eligibility: Inclusion Criteria: * prostate adenocarcinoma * metastatic disease, proven (CT or bone scintigraphy or MRI or positron emission tomography(PET)-CT or X ray) * castration resistance, proven with biology…. Goal: Several drugs are available for metastatic castration resistant prostate cancer such as chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide), in France. The oncologist has to choose between those two type of treatment, without any biological predictor of efficacy for his patient. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Tours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer is being studied. Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression +1 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Progressive, castration-resistant prostate cancer demonstrated during continuous antiandrogen therapy (ADT), defined as 3 PSA rises at…. Goal: This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer. Testosterone can cause the growth of prostate cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy is being studied. Conditions: Recurrent Prostate Cancer • Eligibility: Inclusion Criteria: * Men age ≥18 years who are fluent in English. * Histologically confirmed prostate adenocarcinoma. * Prior surgical castration or active ongoing use of androgen deprivation…. Goal: It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone. Diet supplementation for the prevention or treatment of cancer is attractive, as implementation is relatively easy, even in populations with reduced incomes and resources. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study is being studied. Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer • Eligibility: Inclusion Criteria: 1. Age 65-90 2. Able to understand study procedures and to comply with them for the entire length of the study. 3. Diagnosis of Stage II-III…. Goal: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and makes a difference. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study is being studied. Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma • Eligibility: Inclusion Criteria: * Age \>= 40 years * Histologically confirmed adenocarcinoma of the prostate, (D'Amico risk category intermediate or high risk, localized or locoregional) * Primary treatment is…. Goal: This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing radiation therapy (RT) and androgen deprivation therapy (ADT). ADT effectively slows the growth of prostate cancer cells, thereby enhancing the therapeutic effectiveness of RT. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spinal Anesthesia for Robotic Assisted Laparoscopic Prostatectomy is being studied. Conditions: Prostate Cancer Surgery • Eligibility: Inclusion Criteria: \- Prostate cancer Exclusion Criteria: * Benign prostate disease. Goal: The investigators hypothesised that spinal anesthesia as an adjunct to general anesthesia would facilitate faster recovery and less pain in patients undergoing laparoscopic robotic prostatectomy. A double-blind placebo-controlled study was subsequently designed. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital of North Norway.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer is being studied. Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm +2 • Eligibility: Inclusion Criteria: * Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information or have their legally authorized representative provide…. Goal: The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer. The purpose of Phase II is to test the efficacy (effectiveness) of talazoparib and temozolomide at the maximum tolerated dose, which was determined to be 1mg talazoparib and 75mg/m² temozolomide in the Phase Ib portion of this study. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) is being studied. Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms +1 • Eligibility: Inclusion Criteria: * Male patients diagnosed with metastatic prostate cancer * Initiated apalutamide or enzalutamide for the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Initiation date of…. Goal: The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy is being studied. Conditions: Prostate Adenocarcinoma • Eligibility: Inclusion Criteria: * PRACTICE ELIGIBILITY CRITERIA * All institutions participating in a practice are NCORP components or sub-components * Have a mechanism for delivering SCPs to prostate cancer…. Goal: This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. Phase/Status/Sponsor: Unknown phase; COMPLETED; NRG Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer is being studied. Conditions: Newly Diagnosed Oligometastatic Prostate Cancer • Eligibility: Inclusion Criteria: 1. Biopsy confirmed diagnosis of prostate adenocarcinoma (primary small cell carcinoma of the prostate is not allowed, however adenocarcinoma with neuroendocrine differentiation is allowed) 2. Age…. Goal: This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis. Phase/Status/Sponsor: Unknown phase; COMPLETED; VA Office of Research and Development.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extended Systematic Versus Mri-Assisted pRostate Transperineal Biopsy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Men ≥18 years of age 2. Clinical suspicion of prostate cancer and indicated for prostate biopsy 3. Serum Prostate-specific antigen (PSA) 4-20 ng/mL 4. Digital…. Goal: This is a randomized controlled trial to evaluate the detection of clinically significant prostate cancer (csPCa) by MRI-targeted approach (MRI-arm) versus 24-core transperineal (TP) systematic biopsy (TP-arm). Clinically significant prostate cancer (csPCa) is defined as ISUP (International Society of Urogenital Pathology) Grade group ≥2 prostate cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Chinese University of Hong Kong.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prostate Hyperfixation on PET-choline in Patients With Prostate Cancer: Correlation With MRI and Pathological Data (LOC-CHOLINE) is being studied. Conditions: Prostatic Neoplasms • Eligibility: Inclusion Criteria: * Patients who underwent initial MRI for suspected prostatic neoplasia * Patients who have undergone a PET-choline scan as part of extension work-up. * Patients who…. Goal: In France, when prostate cancer is suspected, multiparametric MRI is the reference imaging technique for tumor localization, and is used to guide biopsies in order to characterize the tumor as accurately as possible. Under the hypothesis that 18 F-choline PET-CT is not inferior to MRI in localizing intra-prostate tumor foci, and could provide complementary data for biopsy, the localizing performance of these two imaging modalities is compared retrospectively, in patients with newly diagnosed prostate tumor treated by surgery. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Brest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Project HERO: Health Empowerment & Recovery Outcomes is being studied. Conditions: Prostate Cancer, Bladder Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on…. Goal: Project HERO is a 12-week study of the efficacy of Body Mind Training (BMT, i.e. Tai Chi and Qigong in this project) for reducing fatigue in male cancer survivors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

STHLM3 AS NorDCaP - a Followup Study of Men on Active Surveillance of Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Men diagnosed with low-risk PC and currently on AS and planned for follow-up with systematic and/or fusion biopsies as following standard of care. Exclusion Criteria:…. Goal: The aim of the STHLM3 AS NorDCaP study is to evaluate the Stockholm3 test in an active surveillance cohort to predict upgrading on rebiopsy. The study follows a paired design, evaluating our proposed protocol for follow up men on active surveillance with Stockholm3 versus the standard protocol according to national guidelines with PSA. Phase/Status/Sponsor: Unknown phase; COMPLETED; Karolinska Institutet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated is being studied. Conditions: 68Ga-PSMA HBED-PET/CT, Prostate Cancer • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed prostate cancer 2. Male, aged \>18 years. 3. Radical treatment for prostate cancer (radiotherapy or surgery) 4. 18F-FMC…. Goal: Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-\[fluorine-18\] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan. Phase/Status/Sponsor: Unknown phase; COMPLETED; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.